|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings GP/FP/Primary care






IM/Ambulatory care 





Gastroenterology 





Respirology 





Key Words: asthma gastro-oesophageal reflux omeprazole
| The first 150 words of the full text of this article appear below. |
METHODS
Design:
randomised, placebo controlled trial.
Allocation:
{concealed*}
.
Blinding:
blinded {patients, healthcare providers, data collectors, outcome assessors, data analysts, monitoring committee, and manuscript writers}
.*
Follow up period:
16 weeks.
Setting:
122 centres in North and South America and Europe.
Patients:
770 patients 1870 years of age (mean age 45 y, 70% women) with stable, adequately treated asthma, FEV1 5080% of predicted with
12% reversibility, and mean morning peak expiratory flow (PEF) <80% predicted. Exclusion criteria included recent use of a proton pump inhibitor and recurrent moderate to severe symptoms of gastro-oesophageal reflux disease (GORD) in patients >40 years of age. During the run in period, patients were excluded if they had >20% decrease in FEV1, or severe exacerbations of GORD or nocturnal respiratory (NOC) or asthma symptoms. Patients were stratified into those with NOC (n = 201), GORD (n = 219), or both NOC and GORD (n
Brian Smith, MD
The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
Relevant Article
Evid. Based Med. 2006 11: 191.
(in Glossary)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |